Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women - PubMed (original) (raw)
Randomized Controlled Trial
. 2007 Sep;92(9):3523-30.
doi: 10.1210/jc.2007-0431. Epub 2007 Jun 26.
Affiliations
- PMID: 17595249
- DOI: 10.1210/jc.2007-0431
Randomized Controlled Trial
Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women
Zehra Berberoglu et al. J Clin Endocrinol Metab. 2007 Sep.
Abstract
Objectives: Our objectives were to evaluate the effect of rosiglitazone on bone metabolism and to assess the association between changes in bone turnover parameters and plasma cytokine levels in postmenopausal diabetic women.
Design: This was a 12-wk open-label randomized-controlled trial.
Patients or other participants: A total of 56 obese postmenopausal women with newly diagnosed diabetes and 26 nondiabetic healthy controls matched for age and body mass index were included in the study.
Interventions: The subjects were instructed to follow a weight-maintenance diet. Half were randomly assigned to receive rosiglitazone 4 mg/d, and the other half remained on diet alone.
Main outcome measures: Before and after the interventions, metabolic bone markers and serum cytokine levels were assessed.
Results: Serum total alkaline phosphatase (ALP) and bone-specific ALP levels were statistically significantly lower 12 wk after initiation of rosiglitazone treatment. There were no statistically significant changes in osteocalcin levels among the three groups or in deoxypyridinoline levels in the rosiglitazone group. At the end of 12 wk, all patients had statistically significantly decreased IL-1beta and TNF-alpha levels compared with baseline. Changes in bone-specific ALP levels showed a moderate negative correlation with the changes in the TNF-alpha levels after rosiglitazone treatment and after diet in the diabetic control group.
Conclusions: Rosiglitazone use is associated with reduced bone formation at earlier stages in postmenopausal diabetic women. The cytokine-lowering effects of rosiglitazone and lifestyle changes could reverse the early inhibitory effect of rosiglitazone therapy on bone formation. Further studies will clarify the long-term effects of rosiglitazone therapy on bone loss and fracture.
Trial registration: ClinicalTrials.gov NCT00440375.
Similar articles
- Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.
Berberoglu Z, Yazici AC, Demirag NG. Berberoglu Z, et al. Clin Endocrinol (Oxf). 2010 Sep;73(3):305-12. doi: 10.1111/j.1365-2265.2010.03784.x. Epub 2010 Feb 10. Clin Endocrinol (Oxf). 2010. PMID: 20148906 Clinical Trial. - Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA. Bilezikian JP, et al. J Clin Endocrinol Metab. 2013 Apr;98(4):1519-28. doi: 10.1210/jc.2012-4018. Epub 2013 Feb 28. J Clin Endocrinol Metab. 2013. PMID: 23450056 Clinical Trial. - The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. Grey A, et al. J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10. doi: 10.1210/jc.2006-2646. Epub 2007 Jan 30. J Clin Endocrinol Metab. 2007. PMID: 17264176 Clinical Trial. - Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE; ADOPT Study Group. Zinman B, et al. J Clin Endocrinol Metab. 2010 Jan;95(1):134-42. doi: 10.1210/jc.2009-0572. Epub 2009 Oct 29. J Clin Endocrinol Metab. 2010. PMID: 19875477 Clinical Trial. - The effect of simvastatin on serum cytokine levels and bone metabolism in postmenopausal subjects: negative correlation between TNF-alpha and anabolic bone parameters.
Tikiz C, Unlü Z, Tikiz H, Ay K, Angin A, Onur E, Var A, Tüzün C. Tikiz C, et al. J Bone Miner Metab. 2004;22(4):365-71. doi: 10.1007/s00774-004-0496-0. J Bone Miner Metab. 2004. PMID: 15221496 Clinical Trial.
Cited by
- Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases.
Martiniakova M, Biro R, Kovacova V, Babikova M, Zemanova N, Mondockova V, Omelka R. Martiniakova M, et al. J Mol Med (Berl). 2024 Apr;102(4):435-452. doi: 10.1007/s00109-024-02418-8. Epub 2024 Feb 16. J Mol Med (Berl). 2024. PMID: 38363329 Free PMC article. Review. - Biochemical Markers of Bone Fragility in Patients with Diabetes. A Narrative Review by the IOF and the ECTS.
Meier C, Eastell R, Pierroz DD, Lane NE, Al-Daghri N, Suzuki A, Napoli N, Mithal A, Chakhtoura M, El-Hajj Fuleihan G, Ferrari S. Meier C, et al. J Clin Endocrinol Metab. 2023 May 8;108(10):e923-36. doi: 10.1210/clinem/dgad255. Online ahead of print. J Clin Endocrinol Metab. 2023. PMID: 37155585 Free PMC article. - Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.
Gu S, Hu X, Shi L, Zhen X, Sun X, Huang M, Gu Y, Dong H. Gu S, et al. J Clin Med. 2022 Nov 30;11(23):7094. doi: 10.3390/jcm11237094. J Clin Med. 2022. PMID: 36498669 Free PMC article. Review. - Thyroid and bone turnover markers in type 2 diabetes: results from the METAL study.
Chen Y, Zhang W, Chen C, Wang Y, Wang N, Lu Y. Chen Y, et al. Endocr Connect. 2022 Mar 31;11(3):e210484. doi: 10.1530/EC-21-0484. Endocr Connect. 2022. PMID: 35196256 Free PMC article. - Omega-3 fatty acid-rich fish oil supplementation prevents rosiglitazone-induced osteopenia in aging C57BL/6 mice and in vitro studies.
Cugno C, Kizhakayil D, Calzone R, Rahman SM, Halade GV, Rahman MM. Cugno C, et al. Sci Rep. 2021 May 14;11(1):10364. doi: 10.1038/s41598-021-89827-8. Sci Rep. 2021. PMID: 33990655 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous